替罗非班
医学
改良兰金量表
溶栓
随机对照试验
安慰剂
特奈特普酶
临床试验
冲程(发动机)
不利影响
麻醉
内科学
缺血性中风
心肌梗塞
缺血
传统PCI
机械工程
替代医学
病理
工程类
作者
Zhen‐Ni Guo,Kejia Zhang,Peng Zhang,Yang Qu,Reziya Abuduxukuer,Thanh N. Nguyen,Hui‐Sheng Chen,Yi Yang
标识
DOI:10.1177/23969873231225069
摘要
Background: Nearly half of patients with acute ischemic stroke who undergo intravenous thrombolysis (IVT) fail to achieve excellent functional outcomes. Early administration of tirofiban after IVT may improve patient outcomes. Objective: To evaluate the efficacy and safety of early tirofiban administration after intravenous tenecteplase in patients with acute ischemic stroke. Methods and design: The ADVENT trial is a multicenter, randomized, parallel-controlled, double-blind clinical trial. A total of 1084 patients undergoing IVT without subsequent endovascular treatment will be recruited from multiple hospitals in China. Subjects will be randomized in a 1:1 ratio to receive tirofiban or placebo, which will be infused within 6 h after IVT until 24 h after IVT, at 0.4 μg/kg/min for 30 min and then at 0.1 μg/kg/min. The primary efficacy outcome is the proportion of patients with excellent functional outcomes (modified Rankin Scale (mRS) ⩽ 1) at 90 days. Secondary outcomes include the proportion of patients with favorable functional outcomes (mRS ⩽ 2) at 90 days and neurological functional assessments evaluated during hospitalization. Symptomatic intracranial hemorrhage will be the primary safety outcome. Mortality and other adverse events will be recorded. Discussion: This pivotal trial will provide important data on the early administration of antiplatelet therapy after IVT and may promote progress in treatment standards. Trial registry: ClinicalTrials.gov (NCT06045156)
科研通智能强力驱动
Strongly Powered by AbleSci AI